9 Oct 2014 17:42

R-Pharm will develop, promote Kyorin medications in Russia

MOSCOW. Oct 9 (Interfax) - Japan's Kyorin Pharmaceutical will present CJSC R-Pharm (Moscow) with the exclusive rights for the production and promotion of a drug for the treatment of overactive bladder, Imidafenacin, on the Russian market and in neighboring countries.

The sides have concluded a relevant agreement, the Russian company said in a statement.

R-Pharm is a Russian pharmaceutical company that develops, tests, produces and markets pharmaceutical products. The company's turnover in 2013 reached 56 billion rubles.

Japan's Kyorin Pharmaceutical, founded in 1923, develops medicines in key areas for the treatment of respiratory, urological and infectious diseases.